Interleukin-22 is associated with progression to acute-on-chronic liver failure and short-term mortality in cirrhosis
Frontiers in Medicine · 03.11.2026 · 13
DOI: 10.3389/fmed.2026.1977342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 03.11.2026. Verfasst von Nikola Mareljic und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, LMU University Hospital, Munich, Germany. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Emerging data show a high potential of prognostic biomarkers in decompensated cirrhosis. Previously, an association between IL-22 and adverse outcomes of decompensated cirrhosis has been shown, but these findings are still to be validated. We therefore analyzed associations between IL-22 plasma levels and clinical endpoints of patients with different patterns of decompensated cirrhosis.
Methods
A post-hoc analysis of consecutive, hospitalized patients with liver cirrhosis was performed. Baseline IL-22 plasma concentrations were quantified and correlated with disease stage and clinical endpoints observed over a 90-day follow-up period.
Results
A total of 254 patients were included in the present study. Plasma IL-22 concentrations in patients with compensated cirrhosis were comparable to those of healthy controls. In contrast, patients experiencing decompensation showed significantly higher IL-22 levels (compensated vs. decompensated, p = 0.004; healthy vs. decompensated, p = 0.014), with further increases noted in those with ACLF (healthy vs. ACLF, p < 0.0001). Of note, patients classified as pre-ACLF demonstrated significantly higher IL-22 concentrations in comparison to chronic, acute stable, and acute unstable decompensated cirrhosis, with a cohort-derived threshold of 11.94 pg/mL showing the highest Youden index for pre-ACLF (AUC = 0.75, 95% CI: 0.67–0.83; p < 0.0001; sensitivity 82%, specificity 63%). Furthermore, IL-22 plasma levels were significantly higher in patients who died within 30 or 90 days ( p = 0.0018 and p = 0.0002). In subgroup analyses this association was confined to patients with ACLF at 30 days ( p = 0.043) and to patients without ACLF at 90 days ( p = 0.011), but it was not observed within the pre-ACLF subgroup.
Conclusions
IL-22 is associated with adverse outcomes and mortality in liver cirrhosis. Moreover, IL-22 concentrations discriminated pre-ACLF from the other courses of acute decompensation. As all thresholds were derived within the present cohort and were not externally validated, these findings are exploratory and need further analysis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine II, LMU University Hospital, Munich, Germany.
- Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Zitieren
APA
Mareljic, N., Langer, M. M., Oeckl, L. S., Weiß, M. J., Allgeier, J., Stadler, H., Yin, Q., Bauschen, A., Zeuzem, N., Graf, C., & Lange, C. M. (2026). Interleukin-22 is associated with progression to acute-on-chronic liver failure and short-term mortality in cirrhosis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1977342
Vancouver
Mareljic N, Langer MM, Oeckl LS, Weiß MJ, Allgeier J, Stadler H, et al. Interleukin-22 is associated with progression to acute-on-chronic liver failure and short-term mortality in cirrhosis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1977342
BibTeX
@article{Mareljic2026,
author = {Mareljic, Nikola and Langer, Mona-May and Oeckl, Lena S and Weiß, Marc J and Allgeier, Julian and Stadler, Helena and Yin, Quan and Bauschen, Alina and Zeuzem, Nicholas and Graf, Christiana and Lange, Christian M},
title = {Interleukin-22 is associated with progression to acute-on-chronic liver failure and short-term mortality in cirrhosis},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1977342}
}
EUVIMED